You are here

Recent Pfizer Press Releases

3/31/16 4:29pm EDT
Pfizer Inc. (NYSE: PFE) today issued the following statement:





A false press release related to drug pricing and linking to a fake web site was anonymously issued earlier today. It was erroneously attributed to Pfizer and should be disregarded. Pfizer is investigating this matter and evaluating its legal options against the parties responsible. Pfizer is committed to engaging in an honest discussion and real dialogue about the issues that matter to patients.

3/30/16 12:41pm EDT
Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination

  • The request was fully anticipated as part of the regulatory process
  • Pfizer and Allergan continue to expect the transaction to close in the second half of 2016

Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today announced that the companies have received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to their previously announced pending combination.

3/30/16 7:45am EDT
3/22/16 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 3, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2016 Performance Report, to be issued that morning.

3/22/16 8:30am EDT
Pfizer Joins The Human Vaccines Project To Help Decode The Immune System

By Pooling Knowledge and Resources From Academia, Government, and Industry Partners, the Consortium Will Evaluate Human Immune Responses with the Goal to Potentially Speed Vaccines and Immunotherapeutic Development

Pfizer Inc. (NYSE:PFE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer.

3/18/16 11:00am EST
Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials

Detailed Results from OCTAVE Induction 1 and 2 Presented During Oral Session at 11th Congress of ECCO

Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program at the 11th Congress of ECCO.

3/16/16 8:00am EST
Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO

Seven Abstracts, Including Pivotal Phase 3 Data in Ulcerative Colitis, Accepted for Presentation

Pfizer Inc. (NYSE:PFE) announced today that seven abstracts reporting on new research for tofacitinib in ulcerative colitis (UC) and Crohn’s disease will be presented at the 11th Congress of ECCO, which will be held March 16-19 in Amsterdam, The Netherlands. Among the abstracts are detailed results from two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program.

3/11/16 1:10pm EST
XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer

XALKORI is the first and only FDA-approved biomarker-driven therapy for ROS1-positive metastatic NSCLC

Pfizer Inc. (NYSE:PFE) today announced that the U.S.

3/9/16 8:00am EST
New Survey Reveals Many Living with Symptoms of Diabetic Nerve Pain Are Undiagnosed Despite Severe and Constant Pain

Cedric “The Entertainer” Discusses Diagnosis and Awareness Disparities Among Diverse Population Groups

Pfizer Inc.

3/9/16 6:45am EST
Pfizer Commences $5 Billion Accelerated Share Repurchase

Accelerated Share Repurchase Assumed in Pfizer’s 2016 Financial Guidance Issued on February 2, 2016

Pfizer Inc. (NYSE:PFE) today announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of Pfizer’s common stock. This agreement is part of Pfizer’s existing share repurchase authorization.

3/8/16 5:00pm EST
Pfizer Announces Publication of Study Results of BeneFIX® Coagulation Factor IX (Recombinant) Once-Weekly Prophylaxis for Hemophilia B

Phase 3 Study showed Prophylaxis With BeneFIX Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Therapy

Pfizer Inc.

3/8/16 1:31pm EST
Pfizer Consumer Healthcare and frog Launch Design Collaborative

New initiative and co-working approach will accelerate innovative solution development to improve health and wellness

frog, the global design and strategy firm, and Pfizer Consumer Healthcare (PCH) today announced the launch of the Design Collaborative, an ongoing initiative that will develop new health and wellness solutions for consumers in the areas of improved sleep, stress management, energy, aging and nutrition. 

2/24/16 11:15am EST
2/19/16 4:35pm EST
Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer

  • First-in-class Therapy Now Approved for Use in a Broader Range of Women
  • New Indication Supported by Results of Phase 3 PALOMA-3 Trial of IBRANCE in Combination with Fulvestrant

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

2/16/16 6:45am EST

Please find Pfizer’s press release and accompanying unaudited Consolidated Statements of Operations and notes thereto at the following hyperlink: 
2/9/16 6:57pm EST
Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications

Pfizer Inc. commends today’s recommendation by the United States (U.S.) Food and Drug Administration’s (FDA) Arthritis Advisory Committee to approve the investigational biosimilar infliximab (CT-P13) across all eligible indications by a vote of 21 to three. Celltrion's proposed biosimilar infliximab, to which Pfizer holds exclusive U.S.

2/8/16 9:30am EST
Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction

Pfizer will continue to manage its commercial operations through two distinct businesses – the innovative products business and the established products business – after the completion of the proposed transaction
Pfizer continues to expect to make a decision about a potential separation of the combined company’s innovative and established businesses by no later than the end of 2018

Pfizer Inc. (NYSE: PFE) today announced the executive leadership team for the combined Pfizer and Allergan plc (NYSE: AGN) business following the close of the proposed transaction.